Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
XOMA Royalty Corp (XOMA)
Standardized SEC financial data for XOMA Royalty Corp — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000791908 · NASDAQ · Pharmaceutical Preparations.
Income statement
USD
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
$29.4M
$38.2M
$6.0M
$4.8M
$28.5M
$52.1M
R&D expense
$170K
$171K
$153K
$143K
$2.9M
$1.7M
SG&A expense
$16.8M
$20.5M
$23.2M
$25.6M
$34.5M
$36.1M
Operating income
$12.4M
$17.5M
-$17.4M
-$41.8M
-$40.0M
$11.4M
EBITDA
$12.4M
—
—
—
—
—
Interest expense
$1.8M
$461K
—
$569K
$13.8M
$13.0M
Pretax income
$11.8M
$15.9M
-$17.1M
-$40.8M
-$19.5M
$31.8M
Income tax
$1.5M
$91K
$15K
$0
$5.7M
$103K
Net income
$13.3M
$15.8M
-$22.6M
-$46.3M
-$19.3M
$31.7M
EPS (diluted)
$0.78
$0.65
$-1.98
$-4.04
$-1.65
$1.46
Standardized from XOMA Royalty Corp's SEC filings — per-share figures split-adjusted. Full history via the API.